Becton Dickinson Acquires NAT Diagnostics

DCN Dx Acquires Biomed Diagnostics

April 25, 2022

Medical Devices

DCN Dx has completed its acquisition of Biomed Diagnostics, Inc., a microbiological testing products company based in White City, Oregon. The deal expands DCN Dx's point-of-use testing and sampling capabilities across human, veterinary, food safety and environmental markets by adding Biomed's InPouch/InTray culture and transport product lines.

Waters Corporation Completes Combination with BD's Biosciences and Diagnostic Solutions Businesses

February 9, 2026

Medical Devices

Waters Corporation has completed its previously announced combination with the Biosciences and Diagnostic Solutions businesses of Becton, Dickinson and Company (BD) via a Reverse Morris Trust, creating a global life sciences and diagnostics company focused on high-volume regulated testing. The combined company is organized into four divisions to align products, services, and informatics across analytical sciences, biosciences, advanced diagnostics and materials sciences; Waters shareholders own ~60.8% and BD shareholders ~39.2% of the combined company.

Natera Acquires Foresight Diagnostics

December 11, 2025

Healthcare Services

Natera has completed its acquisition of Foresight Diagnostics for up to $450 million, consisting of $275 million upfront in stock and up to $175 million in revenue- and reimbursement-linked milestones. The deal brings Foresight’s ultrasensitive PhasED-Seq MRD and liquid-biopsy capabilities into Natera’s Signatera platform, strengthening Natera’s oncology and lymphoma diagnostics capabilities and accelerating clinical and biopharma partnerships.

R-Biopharm AG Acquires AusDiagnostics

June 7, 2022

Biotechnology

German biotechnology company R-Biopharm AG has acquired Australian molecular diagnostics manufacturer AusDiagnostics. The purchase adds AusDiagnostics' multiplex MT-PCR platforms, extraction reagents and laboratory automation capabilities to R-Biopharm's clinical diagnostics portfolio, supporting capability expansion and internationalization into new clinical, veterinary and applied testing markets.

Ott Scientific Acquires American Bionostica

April 1, 2021

Medical Devices

Ott Scientific has acquired American Bionostica, Inc., a developer and manufacturer of specialty lateral flow assays; the acquisition was effective April 1 and ABI will operate inside Ott Scientific’s Ethos Biosciences subsidiary. The American Bionostica team will join Ott Scientific, with expanded research and production capacity planned at Ott Scientific’s new ISO13485/cGMP space in Logan Township, New Jersey.

ICON plc Acquires MolecularMD Corporation

February 21, 2019

Healthcare Services

ICON plc acquired MolecularMD Corporation, a molecular diagnostic specialty laboratory, to expand ICON's molecular diagnostic testing capabilities—including next-generation sequencing and immunohistochemistry—and strengthen support for oncology drug–diagnostic co-development. The acquisition integrates MolecularMD's central laboratory services and client base into ICON's global laboratory network to support precision medicine programs across clinical development phases.